

6 key tailwinds and opportunities to shape the growth of the Generic and Biosimilar Medicines industry

Underlying socioeconomic fundamentals:

Population growth and changing demographics, rising global disease prevalence and containment pressure in healthcare play a key role



Continued trajectory in the innovation pipeline:

While LoE opportunities are continuing to grow, the innovation pipeline continues to expand

Biosimilars opportunity coming to fruition:

Expectation of double-digit growth on the back of streamlined regulatory guidelines and increasing adoption across stakeholders




Digital as an enabler:

Digital and analytics has seen a boost in recent times, and has the capacity to revolutionize commercial models and operations

Continuous innovation to sustain value creation opportunities:

Generic & biosimilar companies will need to invest in capabilities across the value chain to address this opportunity



Blurring of boundaries with adjacent opportunities:

The industry is increasingly finding relevance of its core capabilities across a number of adjacent opportunities

Reference - A Vision for the Global Generic and Biosimilar Medicines Industry (IGBA whitepaper)